Clinical Trial Update: Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for nivolumab in recurrent or metastatic salivary gland carcinoma of the head and neck has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Head and Neck Cancer
• Salivary Gland Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: UNICANCER | Conditions: Salivary Gland Carcinoma, Metastatic Cancer | Phase 2 | Status: COMPLETED